Skip to main content
Clinical Trials/NCT03765112
NCT03765112
Unknown
Not Applicable

Macular Involvement in Diabetic Retinopathy Evaluated With Swept-Source OCT

University of British Columbia1 site in 1 country175 target enrollmentSeptember 20, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Diabetes Mellitus
Sponsor
University of British Columbia
Enrollment
175
Locations
1
Primary Endpoint
Perfusion density
Last Updated
4 years ago

Overview

Brief Summary

This study evaluates micro-vascular changes in patients with diabetes. Results of diseased retinas will be compared to healthy controls.

Detailed Description

The prevalence of diabetes mellitus (DM) is increasing worldwide. Diabetic retinopathy is the most prevalent complication of DM and a leading cause of visual impairment due to closure of capillaries. High-resolution imaging techniques of the retina and its supplying vascular networks can allow novel insight to subtle changes that cannot be appreciated in standard fundus examination. In this study capillary changes of patients with different severity levels of diabetic retinopathy will be investigated with non-invasive imaging technology to better understand the process of disease progression. Imaging will be done with Optical Coherence tomography (OCT) angiography as well as spectral domain OCT and ultra wide-field imaging.

Registry
clinicaltrials.gov
Start Date
September 20, 2018
End Date
March 31, 2023
Last Updated
4 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Eduardo Navajas

Principal Investigator

University of British Columbia

Eligibility Criteria

Inclusion Criteria

  • Age ≥18 Participants can have 1 or 2 study eyes
  • Patient Group:
  • Diabetes mellitus type 1 or 2
  • Study eye with any DR severity level: no DR, mild NPDR, mod NPDR, sev NPDR, PDR

Exclusion Criteria

  • Substantial media opacities that would preclude successful imaging
  • Active intraocular inflammation (grade trace or above) in either eye like infectious conjunctivitis, keratitis, scleritis, endophthalmitis as well as idiopathic or autoimmune-associated uveitis in either eye
  • Structural damage to the center of macula in the study eye
  • History of prior panretinal photocoagulation
  • History of treatment with intravitreal agents over the prior 6 months
  • Macular edema involving the central subfield
  • Prior history of vitrectomy
  • Atrophy of retinal pigment epithelium, subretinal fibrosis, laser scar within foveal avascular zone (FAZ) or organized hard exudate plaques
  • Substantial non-diabetic intraocular pathology in the study eye including retinal vascular occlusion, retinal detachment, macular hole, choroidal neovascularization, macula dystrophies
  • Intraocular surgery (including cataract surgery, YAG laser capsulotomy) in the study eye within 3 months preceding Day 0, or history of corneal transplantation in the study eye

Outcomes

Primary Outcomes

Perfusion density

Time Frame: 6 months

The density of perfused capillaries (metric variable) measured with optical coherence tomography angiography (OCTA) will be compared between the different severity levels of diabetic retinopathy as well as to the control arm.

Secondary Outcomes

  • Areas of different perfusion density(6 months)
  • Foveal avascular zone (FAZ)(6 months)
  • Presence of predominantly peripheral lesions (PPL)(6 months)
  • Retinal layer thickness(6 months)
  • Change in perfusion density in patients with moderate or severe non proliferative diabetic retinopathy (DR) or low risk proliferative DR over the follow up of one year(18 months)

Study Sites (1)

Loading locations...

Similar Trials